MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Wyeth today announced that Michael Kamarck, Ph.D., 57, has been promoted to President, Technical Operations & Product Supply (TO&PS). Dr. Kamarck will be responsible for all aspects of technical operations and product supply for Wyeth, including its Pharmaceutical, BioPharma, Vaccine, Consumer Healthcare and Nutritional units. He succeeds Charles Portwood, 58, who has been appointed to the new role of Executive Vice President, TO&PS Operational Excellence. Both positions will report to Joseph Mahady, President, Wyeth Pharmaceuticals.
"Dr. Kamarck brings strong leadership as well as superb technical and scientific skills to this critical role. He will continue the transformation of our TO&PS organization as we supply medicines of exceptional quality to our customers and patients," says Mr. Mahady.
He joined Wyeth in 2001 and over the next six years successfully led the expansion of Wyeth's global biotechnology manufacturing network. In 2007, Dr. Kamarck was promoted to Executive Vice President, TO&PS where he was responsible for biotechnology and pharmaceutical operations at 13 international sites and for process development of the late-stage pipeline.
Dr. Kamarck began his career in biotechnology and pharmaceutical research for Bayer AG. Before joining Wyeth, he was promoted to Senior Vice President of Operations for the newly formed Bayer Biologicals.
He graduated from Oberlin College and received his Ph.D. in Biochemistry from the Massachusetts Institute of Technology. From 1979 to 1982, Dr. Kamarck was a Fellow of the Leukemia Society of America at Yale University. He is the author of more than 50 peer-reviewed publications and eight issued patents.
Mr. Portwood joined Wyeth in 2001 as President, Global Supply Chain, Wyeth Pharmaceuticals. Through his experience and leadership, he has guided a major transformation of the TO&PS organization.
"Charlie has taken our TO&PS organization to a whole new level of competency and performance," says Mr. Mahady. "He has been instrumental in creating this succession plan and in building a depth of talent in the TO&PS leadership team. We are pleased he will remain an integral part of the Wyeth organization. We are counting on him to support improvement and standardization efforts across the Wyeth manufacturing network."
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.